☰

Gregory S. Zaric, Ph.D. - Publications

Affiliations: 
2000 Stanford University, Palo Alto, CA 
Area:
Operations Research, Health Care Management
Tree Info Similar researchers PubMed Report error

47 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Hannouf MB, Zaric GS, Blanchette P, Brezden-Masley C, Paulden M, McCabe C, Raphael J, Brackstone M. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. The Pharmacogenomics Journal. PMID 31130722 DOI: 10.1038/S41397-019-0089-X  0.348
2019 Qu M, Chen Y, Zaric G, Senan S, Olson R, Harrow S, John-Baptiste A, Gaede S, Mulroy L, Schellenberg D, Senthi S, Swaminath A, Kopek N, Liu M, Warner A, et al. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-Comet International Journal of Radiation Oncology*Biology*Physics. 105: S100-S101. DOI: 10.1016/S0167-8140(19)33384-5  0.354
2018 Hannouf M, Zaric G, Brackstone M. Abstract P4-12-05: Cost-effectiveness analysis of second-generation multi-gene expression prognostic assays compared with the standard 21-gene recurrence score assay to guide adjuvant therapy decisions in women with early stage breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-12-05  0.335
2017 Mahjoub R, Ødegaard F, Zaric GS. Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success. Health Economics. PMID 28627808 DOI: 10.1002/Hec.3522  0.32
2017 Ghamat S, Zaric GS, Pun H. Contracts to Promote Optimal Use of Optional Diagnostic Tests in Cancer Treatment Production and Operations Management. 27: 2184-2200. DOI: 10.1111/Poms.12780  0.317
2016 Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, Rogan P, Hoch JS, Zaric GS. Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary. The Pharmacogenomics Journal. PMID 27019982 DOI: 10.1038/Tpj.2015.94  0.368
2016 Zaric GS. Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine. Pharmacoeconomics. PMID 26899833 DOI: 10.1007/S40273-016-0388-X  0.385
2015 Nguyen TK, Goodman CD, Boldt RG, Warner A, Palma DA, Rodrigues GB, Lock MI, Mishra MV, Zaric GS, Louie AV. Evaluation of Health Economics in Radiation Oncology: A Systematic Review. International Journal of Radiation Oncology, Biology, Physics. PMID 26883562 DOI: 10.1016/j.ijrobp.2015.12.359  0.323
2015 Enns EA, Zaric GS, Strike CJ, Jairam JA, Kolla G, Bayoumi AM. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada. Addiction (Abingdon, England). PMID 26616368 DOI: 10.1111/Add.13195  0.334
2015 Zhang H, Zaric GS. Using price-volume agreements to manage pharmaceutical leakage and off-label promotion. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. 16: 747-61. PMID 25193525 DOI: 10.1007/S10198-014-0626-0  0.308
2013 Fournier DL, Zaric GS. Simulating neonatal intensive care capacity in British Columbia Socio-Economic Planning Sciences. 47: 131-141. DOI: 10.1016/J.Seps.2013.01.001  0.312
2012 Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. Plos One. 7: e45176. PMID 23028828 DOI: 10.1371/Journal.Pone.0045176  0.606
2012 Zaric GS, Brennan AW, Varenbut M, Daiter JM. The cost of providing methadone maintenance treatment in Ontario, Canada. The American Journal of Drug and Alcohol Abuse. 38: 559-66. PMID 22783917 DOI: 10.3109/00952990.2012.694518  0.362
2012 Zecevic AA, Chesworth BM, Zaric GS, Huang Q, Salmon A, McAuslan D, Welch R, Brunton D. Estimating the cost of serious injurious falls in a Canadian acute care hospital. Canadian Journal On Aging = La Revue Canadienne Du Vieillissement. 31: 139-47. PMID 22621825 DOI: 10.1017/S0714980812000037  0.334
2012 Cao JQ, Rodrigues GB, Louie AV, Zaric GS. Systematic review of the cost-effectiveness of positron-emission tomography in staging of non--small-cell lung cancer and management of solitary pulmonary nodules. Clinical Lung Cancer. 13: 161-70. PMID 22133290 DOI: 10.1016/J.Cllc.2011.09.002  0.377
2012 Cipriano LE, Levesque BG, Zaric GS, Loftus EV, Sandborn WJ. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflammatory Bowel Diseases. 18: 1240-8. PMID 21928375 DOI: 10.1002/Ibd.21862  0.303
2011 Malvankar MM, Zaric GS. Incentives for Optimal Multi-level Allocation of HIV Prevention Resources. Infor. 49: 241-246. PMID 23766551 DOI: 10.3138/Infor.49.4.241  0.358
2011 Lasry A, Carter MW, Zaric GS. Allocating funds for HIV/AIDS: a descriptive study of KwaDukuza, South Africa. Health Policy and Planning. 26: 33-42. PMID 20551138 DOI: 10.1093/Heapol/Czq022  0.336
2011 Levesque BG, Cipriano LE, Zaric G, Sandborn WJ, Loftus EV. Cost-Effectiveness of Computed Tomographic Enterography Compared to Magnetic Resonance Enterography in a Simulated Medicare Population With Crohn's Disease Gastroenterology. 140: S-693. DOI: 10.1016/S0016-5085(11)62875-8  0.357
2010 Cipriano LE, Barth W, Zaric GS. The cost-effectiveness of targeted or universal screening for vasa praevia at 18-20 weeks of gestation in Ontario Bjog: An International Journal of Obstetrics and Gynaecology. 117: 1108-1118. PMID 20560948 DOI: 10.1111/J.1471-0528.2010.02621.X  0.355
2009 Brandeau ML, Zaric GS. Optimal investment in HIV prevention programs: more is not always better. Health Care Management Science. 12: 27-37. PMID 19938440 DOI: 10.1007/S10729-008-9074-7  0.618
2009 Zaric GS, Xie B. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 838-45. PMID 19490563 DOI: 10.1111/J.1524-4733.2009.00510.X  0.344
2008 Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 179: 1143-51. PMID 19015565 DOI: 10.1503/Cmaj.080808  0.403
2008 Brandeau ML, Zaric GS, Freiesleben J, Edwards FL, Bravata DM. An ounce of prevention is worth a pound of cure: improving communication to reduce mortality during bioterrorism responses. American Journal of Disaster Medicine. 3: 65-78. PMID 18522248 DOI: 10.5055/Ajdm.2008.0010  0.522
2008 Lasry A, Carter MW, Zaric GS. S4HARA: System for HIV/AIDS resource allocation. Cost Effectiveness and Resource Allocation : C/E. 6: 7. PMID 18366800 DOI: 10.1186/1478-7547-6-7  0.346
2008 Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 28: 359-76. PMID 18349433 DOI: 10.1177/0272989X07312714  0.604
2008 Zaric GS, Bravata DM, Cleophas Holty JE, McDonald KM, Owens DK, Brandeau ML. Modeling the logistics of response to anthrax bioterrorism. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 28: 332-50. PMID 18349432 DOI: 10.1177/0272989X07312721  0.533
2008 Zaric GS. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression. Health Economics. 17: 1277-94. PMID 18186544 DOI: 10.1002/Hec.1332  0.335
2008 Cipriano L, Barth W, Zaric G. PIH10 THE COST-EFFECTIVENESS OF ROUTINE SCREENING FOR VASA PREVIA AT 18-20 WEEKS GESTATION IN ONTARIO Value in Health. 11: A248. DOI: 10.1016/S1098-3015(10)70784-1  0.34
2007 Zaric GS, Brandeau ML. A little planning goes a long way: multilevel allocation of HIV prevention resources. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 27: 71-81. PMID 17237455 DOI: 10.1177/0272989X06297395  0.593
2007 Lasry A, Zaric GS, Carter MW. Multi-level resource allocation for HIV prevention: A model for developing countries European Journal of Operational Research. 180: 786-799. DOI: 10.1016/J.Ejor.2006.02.043  0.359
2006 Bravata DM, Zaric GS, Holty JE, Brandeau ML, Wilhelm ER, McDonald KM, Owens DK. Reducing mortality from anthrax bioterrorism: strategies for stockpiling and dispensing medical and pharmaceutical supplies. Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science. 4: 244-62. PMID 16999586 DOI: 10.1089/Bsp.2006.4.244  0.572
2006 Zaric GS, Hoch JS. Medical savings accounts: opportunities for cost savings? International Transactions in Operational Research. 13: 493-513. DOI: 10.1111/J.1475-3995.2006.00560.X  0.396
2005 Brandeau ML, Zaric GS, de Angelis V. Improved allocation of HIV prevention resources: using information about prevention program production functions. Health Care Management Science. 8: 19-28. PMID 15782509 DOI: 10.1007/S10729-005-5213-6  0.631
2005 Zaric GS, O'brien BJ. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget. Health Economics. 14: 793-803. PMID 15685669 DOI: 10.1002/Hec.976  0.35
2004 Bravata DM, McDonald KM, Owens DK, Wilhelm ER, Brandeau ML, Zaric GS, Holty JE, Liu H, Sundaram V. Regionalization of bioterrorism preparedness and response. Evidence Report/Technology Assessment (Summary). 1-7. PMID 15133889  0.452
2003 Zaric GS. The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysis. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 23: 379-96. PMID 14570296 DOI: 10.1177/0272989X03256883  0.404
2003 Brandeau ML, Zaric GS, Richter A. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis. Journal of Health Economics. 22: 575-98. PMID 12842316 DOI: 10.1016/S0167-6296(03)00043-2  0.741
2003 Zaric G, Bayoumi A, Brandeau M, Owens D. PIN40: THE COST EFFECTIVENESS OF IMPROVED ADHERENCE TO ANTIRETROVIRAL TREATMENT Value in Health. 6: 266. DOI: 10.1016/S1098-3015(10)64017-X  0.609
2002 Zaric GS, Brandeau ML. Dynamic resource allocation for epidemic control in multiple populations. Ima Journal of Mathematics Applied in Medicine and Biology. 19: 235-55. PMID 12828363 DOI: 10.1093/Imammb/19.4.235  0.581
2001 Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction (Abingdon, England). 96: 1267-78. PMID 11672491 DOI: 10.1046/J.1360-0443.2001.96912676.X  0.61
2001 Zaric GS, Brandeau ML. Optimal investment in a portfolio of HIV prevention programs. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 21: 391-408. PMID 11575489 DOI: 10.1177/0272989X0102100506  0.605
2001 Zaric GS, Brandeau ML. Resource allocation for epidemic control over short time horizons. Mathematical Biosciences. 171: 33-58. PMID 11325383 DOI: 10.1016/S0025-5564(01)00050-5  0.571
2000 Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. Journal of Acquired Immune Deficiency Syndromes (1999). 25: 403-16. PMID 11141240 DOI: 10.1097/00042560-200012150-00004  0.61
2000 Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. American Journal of Public Health. 90: 1100-11. PMID 10897189 DOI: 10.2105/Ajph.90.7.1100  0.632
2000 Zaric GS, Brandeau ML, Barnett PG. Methadone maintenance and HIV prevention: a cost-effectiveness analysis Management Science. 46: 1013-1031. DOI: 10.1287/Mnsc.46.8.1013.12025  0.653
1998 Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The Effects of Protease Inhibitors on the Spread of HIV and the Development of Drug-Resistant HIV Strains: A Simulation Study Simulation. 71: 262-275.  0.524
Show low-probability matches.